TrialCurveChemoradiotherapy with S-1 in older patients with esophageal cancer: reconstructed Kaplan–Meier curves
Long-Term Outcomes of Concurrent Chemoradiotherapy With S-1 in Older Patients With Esophageal Cancer: A Secondary Analysis of a Randomized Clinical Trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | JAMA Netw Open. 2026 Mar 27;9(3):e263541. doi: 10.1001/jamanetworkopen.2026.3541 |
|---|---|
| DOI | 10.1001/jamanetworkopen.2026.3541 |
| Registry | NCT02813967 |
| Phase | Phase 3 |
| Conditions | Esophageal Cancer, Chemoradiation |
| Interventions | Radiotherapy 54 Gy, Radiotherapy 60 Gy, S-1 |
| Sponsor | Zhejiang Cancer Hospital |
| Enrolment | 298 |
| Source licence | Figure published under CC BY 4.0 |
Overall survival
From figure panel A · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: CCRT 24.2 months; RT 14.6 months. Survival at 18 months: CCRT 59%; RT 42%. Hazard ratio CCRT vs RT 0.71 (95% CI 0.54–0.92).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| CCRT | 149 | 107 | 24.2 |
| RT | 149 | 122 | 14.6 |
- CCRT vs RT: reconstructed HR 0.71 (95% CI 0.54–0.92)
Landmark survival (reconstructed)
| Time | CCRT | RT |
|---|---|---|
| 6 mo | 88.6% | 87.9% |
| 12 mo | 73.2% | 58.4% |
| 18 mo | 59.1% | 41.6% |
| 24 mo | 51.7% | 34.9% |
| 36 mo | 42.2% | 25.9% |
| 48 mo | 39.4% | 25.2% |
| 60 mo | 33.6% | 24.5% |
Progression-free survival
From figure panel B · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: CCRT 18.7 months; RT 9.3 months. Survival at 18 months: CCRT 50%; RT 32%. Hazard ratio CCRT vs RT 0.70 (95% CI 0.54–0.90).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| CCRT | 149 | 112 | 18.7 |
| RT | 149 | 125 | 9.3 |
- CCRT vs RT: reconstructed HR 0.70 (95% CI 0.54–0.90)
Landmark survival (reconstructed)
| Time | CCRT | RT |
|---|---|---|
| 6 mo | 80.5% | 65.1% |
| 12 mo | 60.4% | 43.6% |
| 18 mo | 50.3% | 31.5% |
| 24 mo | 44.3% | 27.5% |
| 36 mo | 35.5% | 23.3% |
| 48 mo | 32.6% | 23.3% |
| 60 mo | 30.4% | 23.3% |
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- CheckMate 648: Duration of response (per BICR); Overall survival; Progression-free survival (per BICR)
- Gastrectomy and second-line chemotherapy in advanced gastric cancer: Overall survival; Overall survival (IPTW-adjusted); Progression-free survival; Progression
- Neoadjuvant chemoradiotherapy vs adjuvant therapy in ESCC: Disease-free survival; Overall survival
- Preoperative chemoradiotherapy vs chemotherapy in gastric/GEJ cancer: Disease-free survival; Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials